SUGAR LAND--January 31, 2017--Reported by Annette Kreuger, Industrial Info Resources, Incorporated (Sugar Land, Texas)--Immediately following the recent U.S. presidential election, the Pharmaceutical & Biotech Industry benefited from an initial "Trump Bump," thanks in no small part to the new president's pro-business stance. But then President Trump turned a steely eye straight at them, declaring "we have to get our drug industry back," which not only applies to the now-thwarted corporate tax inversion ploys of the past few years, but the actual manufacturing of drugs. Then the president tossed in price controls for good measure.

Within this article: A look at how the Trump administration's policies could, in enacted, affect the drug industry.

Login to Read More